HK Stock Market Move | QYUNS-B(02509) has risen by more than 10%. It plans to continue the annual upper limit of the QX001S framework agreement. The company continues to realize the sustained value of the double resistance.

QYUNS-B (02509) rose more than 10%, as of the time of writing, it rose by 10.11% to HK$20.92, with a turnover of HK$1060.24 million. On the news front, Qilu Trust Bio announced that the board has considered the business needs after the commercialization of Selexis (QX001S) and recommended renewing the upper limit for the continued related party transactions for the three fiscal years from 2026 to 2028 in accordance with the terms of the QX001S framework agreement. Based on the scale of Selexis and the East China business, expected growth and capacity, as well as its business needs, operational conditions, and industry's overall economic outlook, the board recommended setting a new annual upper limit for the three fiscal years from 2026 to 2028 based on the terms of the QX001S framework agreement, with the upper limit of profit sharing expected to increase significantly from RMB 55 million in 2026 to RMB 290 million in 2028. It is worth mentioning that Qilu Trust Bio previously announced a global exclusive cooperation and licensing agreement with Roche for its independently developed long-acting self-releasing dual-antigen QX031N. Under the agreement, Roche will be granted exclusive rights to research, develop, register, manufacture, and commercialize QX031N globally. Qilu Trust Bio will receive an upfront payment of $75 million, as well as up to $995 million in milestone payments and escalating royalties on potential future product sales. China Post Securities believes that the company is a leader in the field of self-releasing innovative drugs in China, and has good accumulation in the field of self-releasing innovative drugs. The company's mature pipeline is gradually entering the cash-in period to enhance hematopoietic capacity, and innovative pipelines are continuously achieving overseas authorization, providing further assurance for the company's stable operation.